← Leaderboards
Maryam Mandana Asgari
University Of Washington
$7,055,850
Attributed
$8,510,808
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,510,808 · 9
By mechanism
R01$4,460,512 · 3
K24$1,891,337 · 1
T32$806,522 · 1
K23$658,585 · 1
R21$358,606 · 1
R03$236,522 · 1
Top collaborators
- Helene Choquet8 shared
- Dennis Roop3 shared
Most similar at University Of Washington
Same institution · by research overlap
- Stephen Mark Schwartz$17,996,380
- Michael G Katze$67,933,838
Others in their field
Top investigators on “Affect”
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Judith S. Currier · University Of California Los Angeles$287,585,588
- Chanza Baytop · Westat, Inc.$271,217,917
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$209,385,844
- David Heimbrook · Leidos Biomedical Research, Inc.$168,138,264
- Daniel R Kuritzkes · Brigham And Women'S Hospital$151,687,019
Research focus
AffectGeneticSquamous Cell CarcinomaDiagnosisAmericanInnovationCohortMalignant NeoplasmsPredispositionEnvironmentRisk FactorsSkin CancerVariantGenome-WideEnvironmental Risk FactorUltraviolet RaysSkin Squamous Cell CarcinomaSmokingSkin DisorderEtiologyResearch PersonnelActinic KeratosisCostBasal Cell Carcinoma
Grant awards (43)
Training in Translational Research of Skin Diseases$311,926
T32 · FY2025 · AR
The Role of Genetic Risk Factors in Keratinocyte Carcinoma Susceptibility$288,410
R01 · FY2025 · CA
Patient oriented research and mentoring program in dermatologic diseases$190,378
K24 · FY2025 · AR · contact PI
The Role of Genetic Risk Factors in Keratinocyte Carcinoma Susceptibility$347,136
R01 · FY2024 · CA
Training in Translational Research of Skin Diseases$229,498
T32 · FY2024 · AR
Patient oriented research and mentoring program in dermatologic diseases$191,384
K24 · FY2024 · AR · contact PI
The Role of Genetic Risk Factors in Keratinocyte Carcinoma Susceptibility$396,556
R01 · FY2023 · CA
PQ3 Cutaneous squamous cell carcinoma: Integrating germline and somatic alterations that underlie tumor progression$374,307
R01 · FY2023 · CA · contact PI
Training in Translational Research of Skin Diseases$265,098
T32 · FY2023 · AR
Patient oriented research and mentoring program in dermatologic diseases$192,370
K24 · FY2023 · AR · contact PI
PQ3 Cutaneous squamous cell carcinoma: Integrating germline and somatic alterations that underlie tumor progression$319,012
R01 · FY2022 · CA · contact PI
Patient oriented research and mentoring program in dermatologic diseases$141,713
K24 · FY2022 · AR · contact PI
Patient oriented research and mentoring program in dermatologic diseases$51,711
K24 · FY2022 · AR · contact PI
The Role of Genetic Risk Factors in Keratinocyte Carcinoma Susceptibility$1
R01 · FY2022 · CA
The Role of Genetic Risk Factors in Keratinocyte Carcinoma Susceptibility$355,029
R01 · FY2021 · CA
PQ3 Cutaneous squamous cell carcinoma: Integrating germline and somatic alterations that underlie tumor progression$255,762
R01 · FY2021 · CA · contact PI
Patient oriented research and mentoring program in dermatologic diseases$194,635
K24 · FY2021 · AR · contact PI
Patient-oriented research and mentoring program in dermatologic diseases$182,535
K24 · FY2021 · AR · contact PI
Identification of genetic loci and pathways underlying hidradenitis suppurativa risk$155,205
R21 · FY2021 · AR · contact PI
The Role of Genetic Risk Factors in Keratinocyte Carcinoma Susceptibility$357,656
R01 · FY2020 · CA
PQ3 Cutaneous squamous cell carcinoma: Integrating germline and somatic alterations that underlie tumor progression$246,546
R01 · FY2020 · CA · contact PI
Identification of genetic loci and pathways underlying hidradenitis suppurativa risk$203,401
R21 · FY2020 · AR · contact PI
Patient-oriented research and mentoring program in dermatologic diseases$184,026
K24 · FY2020 · AR · contact PI
PQ3 Cutaneous squamous cell carcinoma: Integrating germline and somatic alterations that underlie tumor progression$261,874
R01 · FY2019 · CA · contact PI
Patient-oriented research and mentoring program in dermatologic diseases$185,472
K24 · FY2019 · AR · contact PI
Patient-oriented research and mentoring program in dermatologic diseases$187,176
K24 · FY2018 · AR · contact PI
Patient-oriented research and mentoring program in dermatologic diseases$189,937
K24 · FY2017 · AR · contact PI
Genome-wide association study of cutaneous squamous cell carincoma$266,184
R01 · FY2016 · CA · contact PI
Genome-wide association study of cutaneous squamous cell carincoma$348,477
R01 · FY2015 · CA · contact PI
Comparative effectiveness of field-treatments for multiple actinic keratoses$74,855
R03 · FY2015 · AR · contact PI
Comparative Effectiveness of Field-Treatments for Multiple Actinic$3,733
R03 · FY2015 · AR · contact PI
Genome-wide association study of cutaneous squamous cell carcinoma$1
R01 · FY2015 · CA · contact PI
Genome-wide association study of cutaneous squamous cell carcinoma$347,021
R01 · FY2014 · CA · contact PI
Comparative Effectiveness of Field-Treatments for Multiple Actinic$78,968
R03 · FY2014 · AR · contact PI
Genome-wide association study of cutaneous squamous cell carcinoma$296,540
R01 · FY2013 · CA · contact PI
Comparative Effectiveness of Field-Treatments for Multiple Actinic$78,966
R03 · FY2013 · AR · contact PI
NSAID use in Chemoprevention of Squamous Cell Carcinomas$131,717
K23 · FY2009 · AR · contact PI
NSAID use in Chemoprevention of Squamous Cell Carcinomas$131,717
K23 · FY2008 · AR · contact PI
NSAID use in Chemoprevention of Squamous Cell Carcinomas$131,717
K23 · FY2007 · AR · contact PI
NSAID use in Chemoprevention of Squamous Cell Carcinomas$131,717
K23 · FY2006 · AR · contact PI
NSAID use in Chemoprevention of Squamous Cell Carcinomas$131,717
K23 · FY2005 · AR
The role of HPV in squamous cell carcinoma$53,570
F32 · FY2002 · AR
The role of HPV in squamous cell carcinoma$45,154
F32 · FY2000 · AR